Our findings revealed that elevated PELI1 expression was consistently associated with worse overall survival (OS) in several tumor types, including leukemia, acute myeloid leukemia (LAML), LIHC, mesothelioma (MESO) and sarcoma (SARC) (Figure 3A). Here, PELI1 is linked to leukemia.